Cost-effectiveness analysis of anlotinib plus penpulimab as first-line treatment for unresectable hepatocellular carcinoma.
- DOI
- 10.1080/14737167.2026.2719622
- Published
- 2026 Aug 17
- Container
- Expert review of pharmacoeconomics & outcomes research
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/14737167.2026.2719622,
title = {Cost-effectiveness analysis of anlotinib plus penpulimab as first-line treatment for unresectable hepatocellular carcinoma.},
author = {Huang YF and Qin JJ and Wu XQ and Liu H and Luo S and Xu ZQ},
year = {2026},
journal = {Expert review of pharmacoeconomics \& outcomes research},
doi = {10.1080/14737167.2026.2719622},
url = {https://doi.org/10.1080/14737167.2026.2719622}
}RIS
TY - JOUR TI - Cost-effectiveness analysis of anlotinib plus penpulimab as first-line treatment for unresectable hepatocellular carcinoma. AU - Huang YF AU - Qin JJ AU - Wu XQ AU - Liu H AU - Luo S AU - Xu ZQ PY - 2026 JO - Expert review of pharmacoeconomics & outcomes research DO - 10.1080/14737167.2026.2719622 UR - https://doi.org/10.1080/14737167.2026.2719622 ER -
APA
YF, H., JJ, Q., XQ, W., H, L., S, L., & ZQ, X. (2026). Cost-effectiveness analysis of anlotinib plus penpulimab as first-line treatment for unresectable hepatocellular carcinoma.. Expert review of pharmacoeconomics & outcomes research. https://doi.org/10.1080/14737167.2026.2719622
Source records
- pubmed · retrieved 2026-09-25T08:40:12.221Z